Leticia Colyn

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma.

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma.

Journal: Frontiers in cell and developmental biology

Published: December 11, 2025

Keap1 Deletion Rescues Cell Death Associated With Gpx4 Loss in Hepatocytes During Acute Liver Injury.

Keap1 Deletion Rescues Cell Death Associated With Gpx4 Loss in Hepatocytes During Acute Liver Injury.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 27, 2024

Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.

Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.

Journal: Gut

Published: May 31, 2024

Loss of Toll-like receptor 9 protects from hepatocellular carcinoma in murine models of chronic liver disease.

Loss of Toll-like receptor 9 protects from hepatocellular carcinoma in murine models of chronic liver disease.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: March 21, 2024

New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.

New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 05, 2022

Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease.

Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease.

Journal: Cancers

Published: December 02, 2021

Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.

Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.

Journal: Cancers

Published: December 01, 2020

Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

Journal: Cells

Published: September 18, 2020

Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.

Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.

Journal: JHEP reports : innovation in hepatology

Published: July 01, 2020

Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach.

Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach.

Journal: Cancers

Published: June 04, 2020

Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.

Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: February 05, 2020

Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge.

Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge.

Journal: Oncogene

Published: December 29, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026